Lili L.’s Post

🧬 𝐏𝐚𝐬𝐭, 𝐩𝐫𝐞𝐬𝐞𝐧𝐭, 𝐚𝐧𝐝 𝐟𝐮𝐭𝐮𝐫𝐞 𝐨𝐟 𝐠𝐞𝐧𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲 Gene therapy was and is transformative. Starting with the EMA and FDA approvals in 2009 and 2010, through to recent CRISPR-based technologies, it shows that the development of this area is accelerating. There are still some issues to solve, such as undesired immune responses or complex delivery mechanisms, but I believe that in the near future, we will see the incorporation of gene and cell therapies into more therapeutic areas. A very nice read: https://lnkd.in/dWq8EBzi #biotech #pharma #genetherapy #geneediting #funding #womeninbusinesss #drjojo ---------- Hi! I am Joanna, and my friends call me Dr Jojo 🌸 𝐈 𝐭𝐚𝐥𝐤 𝐚𝐛𝐨𝐮𝐭 𝐢𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧 𝐚𝐧𝐝 𝐛𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐢𝐧 𝐩𝐡𝐚𝐫𝐦𝐚 𝐚𝐧𝐝 𝐛𝐢𝐨𝐭𝐞𝐜𝐡 ♻️ Share this if you find it interesting 🔔 Follow for insights you won't want to miss

🚀 Advances in AAV Manufacturing for Gene Therapy! Gene therapy has made incredible strides, but scaling up AAV production for broad accessibility is still a challenge. From plasmid construction to AAV vector production and purification, each step impacts therapeutic quality and cost. Our blog dives into the nuances of the AAV manufacturing process and the innovative solutions helping to optimize production, reduce impurities, and ensure therapeutic efficacy. Discover how advances like Form Bio’s AI-driven In Silico Assays™ and new methods in quality control are paving the way for efficient, scalable gene therapy. Read more! https://hubs.li/Q02YhLYD0 #genetherapy #AAV #AI #insilico

I've been seeing a lot about Ori Biotech's IRO cell and gene therapy manufacturing platform. With over 95% of patients left without access to cell and gene therapies, overcoming current challenges in manufacturing remains a critical barrier to scaling cell and gene therapies. The platform has the potential to shave years off therapy development timelines, reducing labor by up to 70%, reducing the cost of goods by up to 50%, cutting processing times by up to 25%, and accelerating #tech transfer times from months to weeks. The IRO platform is a keen example of how #biotech is working to enable widespread patient access to life-saving therapies.

#BioPharmaBoardRoomTrendline2025 In a detailed interview with BioPharma BoardRoom, @Kerstin Pohl, Senior Global Marketing Manager for Gene Therapy & Nucleic Acid at SCIEX, delves into the analytical challenges gene therapy developers face as the field evolves in 2025. From addressing small sample sizes and diverse delivery mechanisms to pioneering advancements in mass spectrometry and capillary electrophoresis, SCIEX is at the forefront of driving innovation in biotherapeutics. Join us as Pohl shares how SCIEX’s cutting-edge technologies are shaping the future of quality, accessibility, and regulatory compliance in gene therapy.

Exciting News in Cell and Gene Therapy Manufacturing! Ori Biotech has just unveiled its groundbreaking IRO platform, designed to revolutionize the production of cell and gene therapies (CGT). This innovative technology promises to cut manufacturing costs by 50% and reduce production time by 25%, making these advanced treatments more accessible to patients worldwide. Key highlights of the IRO platform: - Automates and standardizes labor-intensive processes. - Produces a single patient dose in just 2-3 days (down from 8-10 days). - Reduces typical therapy costs significantly. - Compact design fits 30 units in a space no larger than a two-car garage. - Cloud technology for real-time data monitoring and process efficiency. Ori Biotech's CEO, Jason Foster, emphasizes the urgent need for such advancements: "We’re in a constrained supply environment. We just can’t physically treat enough patients with cell and gene therapies." With its commercial debut expected in early 2025, Ori’s IRO platform is poised to make a substantial impact on the CGT field. Learn more about how Ori Biotech is paving the way for more efficient and cost-effective cell and gene therapies. #Biotech #CellAndGeneTherapy #Innovation #Healthcare #OriBiotech #Manufacturing

🚀 The UK is Paving the Way in Cell and Gene Therapy! 🚀 In recent reports, the UK has solidified its position as a global leader in the cell and gene therapy sector, showcasing cutting-edge innovations and growing investments that are transforming patient care. The potential of these therapies is staggering, offering new hope for previously untreatable conditions. According to Matthew Durdy, CEO of the Cell and Gene Therapy Catapult: "The UK can take the lead in harnessing these therapies to deliver life-changing benefits to patients and economic growth to the nation." 🌍 Steve Bates OBE FMedSci, CEO of the BioIndustry Association (BIA), also emphasises: "The UK's leadership in cell and gene therapy is a testament to our unwavering dedication to patient-centric advancements that rewrite the boundaries of healthcare." 💡 With a 26% increase in investment in 2024 alone and 84 therapies in clinical development, the UK is not only leading Europe but also pushing the boundaries of biotechnology on a global scale. https://lnkd.in/emwrbMHR #Innovation #Biotechnology #HealthcareRevolution #GeneTherapy #CellTherapy #UKLeadership #STEM #CuttingEdge #FutureOfHealth #LifeSciences

The key to leveraging AI in gene therapy development is to be able to recognize which stages of development it can be a strategic advantage.🚀 Discover the benefits and impact of AI-based tools on the advancement of gene therapy development looking at some specific use cases where AI can: ✔️ Reduce costs ✔️ Alleviate risks ✔️ Speed up development Learn more here👇 https://bit.ly/3VHLuk9 #AI #Genetherapy #R&D #DoMoreScience

The theme from D1 Cell and Gene Meeting on the Mesa (Alliance for Regenerative Medicine) was about coming down to earth & atomizing the commercialization and industrialization problems of cell and gene therapy into attainable building blocks. Check out my convos w/ Dyno Therapeutics, Profluent, Astellas Gene Therapies / Astellas Pharma, Autolomous. Stay cool!

🚀 Exciting news in biotech this week! 🧬 First Gene Therapy Approved for Brain Delivery The FDA has approved the first-ever gene therapy for patients with aromatic L-amino acid decarboxylase (AADC) deficiency. This groundbreaking treatment from PTC Therapeutics is administered directly to the brain, marking a significant advancement in how gene therapies can be applied. AADC deficiency is a rare genetic disorder that affects neurotransmitter production, leading to severe motor and cognitive disabilities. This approval represents hope for affected families and highlights the potential of targeted therapies in rare diseases. 💡 Early-Stage Innovation PTC Therapeutics, a company known for its focus on rare diseases, has taken a bold step in the gene therapy space. Their collaboration with academic institutions has been crucial in developing this treatment. This approval is a testament to the importance of early-stage biotechs in pushing the boundaries of medical science. 🤝 Collaboration is Key In the landscape of biopharma, partnerships are vital. Smaller companies like PTC Therapeutics often collaborate with larger organizations and research institutions to bring innovative solutions to market. These collaborations not only provide the necessary resources but also foster an environment where new ideas can thrive. 📈 Looking Ahead As we celebrate this milestone, it's essential to support and nurture early-stage biotechs that are ready to take on challenges in rare diseases and beyond. The future of biotech relies on the creativity and determination of these innovative companies. Stay tuned for more updates as we continue to champion the incredible work happening in the biotech sector!